Assessing the Prognosis of Patients with Metastatic or Recurrent Non-small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy

Seweryn Gałecki; Marzena Kysiak; Emilia Kozłowska; Agata Małgorzata Wilk; Rafał Suwiński; Andrzej Świerniak

doi:10.1007/978-3-031-38430-1_14

Assessing the Prognosis of Patients with Metastatic or Recurrent Non-small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy

Seweryn Gałecki
, Marzena Kysiak
, Emilia Kozłowska
, Agata Małgorzata Wilk
, Rafał Suwiński
, Andrzej Świerniak

Maria Sklodowska-Curie Institute of Oncology

Wyniki badań: Rozdział w książce/raport/materiał konferencyjny › Wkład w konferencję › recenzja

Abstrakt

Locally advanced non-small cell lung cancer (NSCLC) is characterized by poor prognosis and is the leading cause of cancer-related deaths worldwide. The main problem in NSCLC is treatment resistance and a high potential for progression and metastasis, which results in low survival rates for patients. Immunotherapy (IO) alone or combined with chemotherapy and targeted therapies, while dedicated to selective subgroups of patients, replaced traditional cytotoxic therapies (radiotherapy or chemotherapy) in advanced stages of disease. Therefore, it’s important to search for new features that may help predict the effectiveness of currently available therapies. The paper presents preliminary results of exploratory data and survival analyses (Kaplan-Meier survival curves, uni- and multivariate Cox proportional hazards models), indicating potential factors that may help stratify the group of patients to select the appropriate treatment.

Język oryginału	angielski
Tytuł publikacji goszczącej	The Latest Developments and Challenges in Biomedical Engineering - Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering
Redaktorzy	Paweł Strumiłło, Artur Klepaczko, Michał Strzelecki, Dorota Bociąga
Wydawca	Springer Science and Business Media Deutschland GmbH
Strony	175-186
Liczba stron	12
ISBN (drukowany)	9783031384295
Identyfikatory DOI	https://doi.org/10.1007/978-3-031-38430-1_14
Status publikacji	Opublikowano - 2024
Wydarzenie	Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering, PCBEE 2023 - Lodz, Polska Czas trwania: 27 wrz 2023 → 29 wrz 2023

Seria publikacji

Nazwa	Lecture Notes in Networks and Systems
Tom	746 LNNS
ISSN (drukowany)	2367-3370
ISSN (elektroniczny)	2367-3389

Konferencja

Konferencja	Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering, PCBEE 2023
Kraj/Terytorium	Polska
Miejscowość	Lodz
Okres	27/09/23 → 29/09/23

Cele SDG ONZ

Ten wynik przyczynia się do realizacji następujących celów zrównoważonego rozwoju

Cel 3 Dobre zdrowie i dobre samopoczucie

Obszary tematyczne ASJC Scopus

Inżynieria sterowania i systemów
Przetwarzanie sygnałów
Sieci komputerowe i komunikacja

Uzyskaj dostęp do dokumentu

10.1007/978-3-031-38430-1_14

Inne pliki i linki

Link do publikacji w Scopus

Cytowanie

Gałecki, S., Kysiak, M., Kozłowska, E., Wilk, A. M., Suwiński, R., & Świerniak, A. (2024). Assessing the Prognosis of Patients with Metastatic or Recurrent Non-small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy. W P. Strumiłło, A. Klepaczko, M. Strzelecki, & D. Bociąga (Red.), The Latest Developments and Challenges in Biomedical Engineering - Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering (str. 175-186). (Lecture Notes in Networks and Systems; Tom 746 LNNS). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/978-3-031-38430-1_14

Gałecki, Seweryn ; Kysiak, Marzena ; Kozłowska, Emilia i in. / Assessing the Prognosis of Patients with Metastatic or Recurrent Non-small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy. The Latest Developments and Challenges in Biomedical Engineering - Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering. redaktor / Paweł Strumiłło ; Artur Klepaczko ; Michał Strzelecki ; Dorota Bociąga. Springer Science and Business Media Deutschland GmbH, 2024. str. 175-186 (Lecture Notes in Networks and Systems).

@inproceedings{11b2d1da6d8f42e2bc5e81df5c7a90df,

title = "Assessing the Prognosis of Patients with Metastatic or Recurrent Non-small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy",

abstract = "Locally advanced non-small cell lung cancer (NSCLC) is characterized by poor prognosis and is the leading cause of cancer-related deaths worldwide. The main problem in NSCLC is treatment resistance and a high potential for progression and metastasis, which results in low survival rates for patients. Immunotherapy (IO) alone or combined with chemotherapy and targeted therapies, while dedicated to selective subgroups of patients, replaced traditional cytotoxic therapies (radiotherapy or chemotherapy) in advanced stages of disease. Therefore, it{\textquoteright}s important to search for new features that may help predict the effectiveness of currently available therapies. The paper presents preliminary results of exploratory data and survival analyses (Kaplan-Meier survival curves, uni- and multivariate Cox proportional hazards models), indicating potential factors that may help stratify the group of patients to select the appropriate treatment.",

keywords = "Curative treatment, Exploratory data analysis, Non-small cell lung cancer, Overall survival, Palliative treatment",

author = "Seweryn Ga{\l}ecki and Marzena Kysiak and Emilia Koz{\l}owska and Wilk, \{Agata Ma{\l}gorzata\} and Rafa{\l} Suwi{\'n}ski and Andrzej {\'S}wierniak",

note = "Publisher Copyright: {\textcopyright} 2024, The Author(s), under exclusive license to Springer Nature Switzerland AG.; Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering, PCBEE 2023 ; Conference date: 27-09-2023 Through 29-09-2023",

year = "2024",

doi = "10.1007/978-3-031-38430-1\_14",

language = "English",

isbn = "9783031384295",

series = "Lecture Notes in Networks and Systems",

publisher = "Springer Science and Business Media Deutschland GmbH",

pages = "175--186",

editor = "Pawe{\l} Strumi{\l}{\l}o and Artur Klepaczko and Micha{\l} Strzelecki and Dorota Boci{\c a}ga",

booktitle = "The Latest Developments and Challenges in Biomedical Engineering - Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering",

address = "Germany",

}

Gałecki, S, Kysiak, M, Kozłowska, E, Wilk, AM, Suwiński, R & Świerniak, A 2024, Assessing the Prognosis of Patients with Metastatic or Recurrent Non-small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy. w P Strumiłło, A Klepaczko, M Strzelecki & D Bociąga (red), The Latest Developments and Challenges in Biomedical Engineering - Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering. Lecture Notes in Networks and Systems, tom 746 LNNS, Springer Science and Business Media Deutschland GmbH, str. 175-186, Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering, PCBEE 2023, Lodz, Polska, 27/09/23. https://doi.org/10.1007/978-3-031-38430-1_14

Assessing the Prognosis of Patients with Metastatic or Recurrent Non-small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy. / Gałecki, Seweryn; Kysiak, Marzena; Kozłowska, Emilia i in.
The Latest Developments and Challenges in Biomedical Engineering - Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering. red. / Paweł Strumiłło; Artur Klepaczko; Michał Strzelecki; Dorota Bociąga. Springer Science and Business Media Deutschland GmbH, 2024. str. 175-186 (Lecture Notes in Networks and Systems; Tom 746 LNNS).

Wyniki badań: Rozdział w książce/raport/materiał konferencyjny › Wkład w konferencję › recenzja

TY - GEN

T1 - Assessing the Prognosis of Patients with Metastatic or Recurrent Non-small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy

AU - Gałecki, Seweryn

AU - Kysiak, Marzena

AU - Kozłowska, Emilia

AU - Wilk, Agata Małgorzata

AU - Suwiński, Rafał

AU - Świerniak, Andrzej

PY - 2024

Y1 - 2024

N2 - Locally advanced non-small cell lung cancer (NSCLC) is characterized by poor prognosis and is the leading cause of cancer-related deaths worldwide. The main problem in NSCLC is treatment resistance and a high potential for progression and metastasis, which results in low survival rates for patients. Immunotherapy (IO) alone or combined with chemotherapy and targeted therapies, while dedicated to selective subgroups of patients, replaced traditional cytotoxic therapies (radiotherapy or chemotherapy) in advanced stages of disease. Therefore, it’s important to search for new features that may help predict the effectiveness of currently available therapies. The paper presents preliminary results of exploratory data and survival analyses (Kaplan-Meier survival curves, uni- and multivariate Cox proportional hazards models), indicating potential factors that may help stratify the group of patients to select the appropriate treatment.

AB - Locally advanced non-small cell lung cancer (NSCLC) is characterized by poor prognosis and is the leading cause of cancer-related deaths worldwide. The main problem in NSCLC is treatment resistance and a high potential for progression and metastasis, which results in low survival rates for patients. Immunotherapy (IO) alone or combined with chemotherapy and targeted therapies, while dedicated to selective subgroups of patients, replaced traditional cytotoxic therapies (radiotherapy or chemotherapy) in advanced stages of disease. Therefore, it’s important to search for new features that may help predict the effectiveness of currently available therapies. The paper presents preliminary results of exploratory data and survival analyses (Kaplan-Meier survival curves, uni- and multivariate Cox proportional hazards models), indicating potential factors that may help stratify the group of patients to select the appropriate treatment.

KW - Curative treatment

KW - Exploratory data analysis

KW - Non-small cell lung cancer

KW - Overall survival

KW - Palliative treatment

UR - https://www.scopus.com/pages/publications/85172336317

U2 - 10.1007/978-3-031-38430-1_14

DO - 10.1007/978-3-031-38430-1_14

M3 - Conference contribution

AN - SCOPUS:85172336317

SN - 9783031384295

T3 - Lecture Notes in Networks and Systems

SP - 175

EP - 186

BT - The Latest Developments and Challenges in Biomedical Engineering - Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering

A2 - Strumiłło, Paweł

A2 - Klepaczko, Artur

A2 - Strzelecki, Michał

A2 - Bociąga, Dorota

PB - Springer Science and Business Media Deutschland GmbH

T2 - Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering, PCBEE 2023

Y2 - 27 September 2023 through 29 September 2023

ER -

Gałecki S, Kysiak M, Kozłowska E, Wilk AM, Suwiński R, Świerniak A. Assessing the Prognosis of Patients with Metastatic or Recurrent Non-small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy. W Strumiłło P, Klepaczko A, Strzelecki M, Bociąga D, redaktorzy, The Latest Developments and Challenges in Biomedical Engineering - Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering. Springer Science and Business Media Deutschland GmbH. 2024. str. 175-186. (Lecture Notes in Networks and Systems). doi: 10.1007/978-3-031-38430-1_14

Assessing the Prognosis of Patients with Metastatic or Recurrent Non-small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy

Abstrakt

Seria publikacji

Konferencja

Cele SDG ONZ

Obszary tematyczne ASJC Scopus

Uzyskaj dostęp do dokumentu

Inne pliki i linki

Fingerprint

Cytowanie